Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited announced a change in the director’s interest, with William Burns exercising options to acquire 120,000 ordinary shares, increasing his total holdings to 226,250 shares. This transaction, valued at A$157,200, reflects strategic financial management and potentially strengthens the director’s commitment to the company’s future growth.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on developing and commercializing innovative cellular medicines. The company primarily targets the treatment of inflammatory diseases, cardiovascular diseases, and back pain, leveraging its proprietary mesenchymal lineage cell technology.
Average Trading Volume: 4,970,723
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.3B
Learn more about MSB stock on TipRanks’ Stock Analysis page.